Do we need to consider inflammatory markers when we treat atherosclerotic disease?

被引:84
作者
Athyros, Vasilios G. [1 ]
Kakafika, Anna I. [1 ]
Karagiannis, Asterios [1 ]
Mikhailidis, Dimitri P. [2 ]
机构
[1] Aristotle Univ Thessaloniki, Hippocration Hosp, Sch Med, Propedeut Dept Internal Med 2, Thessaloniki, Greece
[2] Univ London, Univ Coll London, Royal Free Univ Coll Med Sch, Royal Free Hosp,Dept Clin Biochem,Vasc Prevent Cl, London, England
关键词
cardiovascular disease; non-alcoholic fatty liver disease; autoimmune disease; inflammation; C-reactive protein; statins; angiotensin II blockade;
D O I
10.1016/j.atherosclerosis.2008.02.026
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This review considers the value of monitoring inflammatory markers as a guide to selecting appropriate drugs in patients at high risk of cardiovascular disease (CVD). Clinical and experimental studies investigated inflammation in patients with acute coronary syndromes (ACS), stable coronary artery disease (CAD) and diabetes mellitus (DM) or metabolic syndrome (MetS), non-alcoholic fatty liver disease (NAFLD) or systemic autoimmune diseases (SAD). Evidence suggests that in these high risk groups inflammation plays a role in the extent and severity of atherosclerosis. Simple inflammatory markers (e.g. C-reactive protein and fibrinogen) can be monitored cost effectively and may influence the selection of drugs that can normalize both traditional CVD risk factors and inflammation. However, this concept requires proof in appropriately designed trials that include clinically relevant end points. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 82 条
[81]  
Yusuf S, 2000, NEW ENGL J MED, V342, P145
[82]  
Zwaka TP, 2001, CIRCULATION, V103, P1194